All News
Is a Biomarker for Adverse Pregnancy Outcomes on the Horizon?
With a better understanding of pathophysiology, improved management guidelines, available medications, and a multidisciplinary approach, pregnancy for lupus patients has become more feasible. Despite these improvements, some patients still experience poor outcomes, highlighting the need for biomarkers that can predict these risks. An abstract presented at #EULAR2024 (POS1393) explored this possibility.
Read Article
#wasup in #GCA?
#upadacitinib +RCT in #temporal #arteritis LBA0001
Residual #inflammation in 1/3 of pts at 6 mo #Rx w #TCZ on repeat TA Bx
OP0621
#PMR cases
#Leflunomide beats #MTX for
#pred sparing
⬇️relapses
But MTX dose was low
POS0280
#EULAR2024 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
New #JAKi #disease #results
#Baricitinib in #alopecia #areata esp 4mg/d
#Upadacitinib in Crohn’s
#Upa in #polyarticular #JIA & kid #PsA
+RCT of UPA in #GCA
Awaiting results of #SLE
With #deucravicitinib & UPA #RCTs
#EULAR2024 @eular_org @RheumNow
Janet Pope Janetbirdope ( View Tweet)
#Behcet’s #syndrome is increasing in the UK
? ⬆️ Detection
? Changing population demographics
? Other reasons
Poster discussion POS0258
#EULAR2024 @RheumNow @eular_org
@Pr1yankaC https://t.co/SEzmJnFMhM
Links:
Janet Pope Janetbirdope ( View Tweet)
When would I use
#Aclasta vs #Prolia since #denosumab has LESS #fractures
▶️younger women with #osteoporosis requiring Rx due to long safety
▶️less wearing off when stopping it
▶️noncompliant Pts as prolia reverses effect when dose is missed
@RheumNow #EULAR2024 @eular_org https://t.co/0RTGx0sCTd
Janet Pope Janetbirdope ( View Tweet)
Agree!
Liz Volkmann said it straight
Unsustainable RCTs in ILD trials in #scleroderma
Why
Can’t recruit
~same pool of early #dcSSc design RCT
UNETHICAL a to have a progressing #scleroderma-ILD Pt on failed background #MMF + placebo for 1 yr
🙏🏻 #EULAR2024 @RheumNow @eular_org https://t.co/29oFEazwmM
Janet Pope Janetbirdope ( View Tweet)
I think if we’re worried about JAK inhibitor safety, we need to be doing it right.
I wrote this for @RheumNow for #EULAR2024 ahead of my debate against @Janetbirdope, but also drew my inspiration from @RADoctor in @ACR_Journals - a must read:
https://t.co/RA6ktQAzqO https://t.co/lltDbtxpAg
Links:
David Liew drdavidliew ( View Tweet)
🗓️ Our abstract on psychosocial determinants of health in #RheumatoidArthritis will be presented at #EULAR2024
📹 Watch my video on @RheumNow for a sneak preview!
📍 Join me to hear more on #PARE Poster Tour IV, Friday 14th June, 12:00 - 13:00 CEST
https://t.co/rDTJVukD6j
Mrinalini Dey DrMiniDey ( View Tweet)
➡️POS0591 Are there sex differences in risk & outcomes of stroke in patients with #RA?
📈Stroke risk in RA increased compared to general population
🫀Not fully explained by traditional risk factors or AF
📊Stroke-related mortality differs in women vs men
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
POS0592 Increased overall & cause-specific mortality in population-based cohort of people with incident #RA
Higher mortality in RA vs gen pop but this has decreased after 2000 & better 10-year survival
Severe causes of mortality incl cardiac higher in RA
EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
POS1035 FVC & risk of lung transplant & mortality in #RAILD
50% pts had FVC % predicted decline in ~6.5yrs
2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression
#EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #Sjogren was 3 x higher than the general population due to active disease & comorbidities. Call for better MDT approach in management @RheumNow https://t.co/EevoT4jkqr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11
Peter Nash drpnash ( View Tweet)
#EULAR2024 POS1420 A cohort study with 1/3 each with GCA, PMR and GCA+PMR found that at 6mth, 16% of patients had new diabetes/diabetes worsened. Worse in GCA+PMR group with the greatest GC accumulation. Call for better GC-sparing strategy @RheumNow https://t.co/ex7u83bVfj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0742 A single cohort study showed for non-criteria #APS, cardiac manifestation (valvular dysfunction & regurgitation) was more common in Triple Ab+ vs Non-Triple Ab. We should monitor and consider an echocardiogram for this group of patient @RheumNow https://t.co/VxFUSpjaG1
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Active day of learning and discussion with a Round Up from Day 3 of #EULAR2024 with @RheumNow https://t.co/yzLsPNDM5d
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow
https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0024 Lymphopenia, anemia, & low Plt are assoc with disease activity & damage accrual in #lupus. Post-hoc analysis of RCTs + LTE showed Anifrolumab normalised these Haem parameters vs PBO. May improve fatigue-associated with anaemia @RheumNow https://t.co/GF8aKU0Z5x
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
SLE Preview: abolishing refractory with CAR-T and better B-cell therapies
Despite advancements, some SLE patients remain refractory to belimumab and off-label rituximab, the main B cell-targeted therapies in the last 15 years.
https://t.co/778buNUq1C https://t.co/4ub8VbrLb6
Dr. John Cush RheumNow ( View Tweet)
📄 You can now read my article on #CardiovascularDisease, #Stroke & #Mortality @RheumNow!
🌟 Featuring 2 cohort studies from @MayoClinic, presented at #EULAR2024
🔗 https://t.co/b639vE5hSA
@MyasoedovaElena
Mrinalini Dey DrMiniDey ( View Tweet)